3Gustafsson L L, Wettermark B, Godman B, et al. The ' Wise List' -A Comprehensive Concept to Select, Communi- cate and Achieve Adherence to Recommendations of Essen- tial Drugs in Ambulatory Care in Stockholm [ J ]. Basic & Clinical Pharmacology & Toxicology, 2011, 108 ( 4 ) : 224-233.
4OECD. Health at a Glance 2009: OECD Indicators [ R ]. Paris, 2010.
5China National Health Economics Institute. National Health Accounts Report 2012[ R]. Beijing, 2012.
6OECD. Pharmaceutical Pricing Policies in a Global Market OECD Health Policy Studies, Directorate for Employment, Labour and Social Affairs, Health Division [ R ]. Paris, 2008.
7National Institute for Health and Clinical Excellence . The guidelines manual [ EB/OL]. [ 2012-04-15 ]. www. nice. org. uk.
8Mossialos E, Mrazek M, Walley T. Regulating Pharmaceuti- cals In Europe : Striving For Efficiency, Equity, And Quality [ R]. European Observatory of Health Policy and Systems: WHO 2004.
9The selection and use of essential medicines: report of the WHO Expert Committee [ R ]//WHO technical report series 946. Geneva: WHO, 2007.
10WHO. WHO Expert Committee for the Selection of Essen- tial Medicines [ EB/OL]. [2012434-15 ]. http://www. who. int/selection_medicines/committees/en/index, html.
